Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

Patente, Thiago A.; Pinho, Mariana Pereira; Oliveira, Azauri Albano de; Evangelista, Gabriela Coeli Menezes; Bergami-Santos, Patrícia Cruz; Barbuto, José Alexandre Marzagão

doi:10.3389/fimmu.2018.03176

Cited by 319 publications

(292 citation statements)

References 280 publications

Supporting

Mentioning

271

Contrasting

Unclassified

Order By: Relevance

“…DC are the main antigen processing cells of the immune system [44] that are able to present the peptides antigen complexed in both major histocompatibility class I and class II (MHC-I and MHC-II, respectively). If a DC encounters the native virus form, it can be able to process it and present its peptides complexed with MHC-II to CD4 T cells for further actions.…”

Section: B Sars-cov-2 Disease Modelmentioning

confidence: 99%

In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform

Russo

Pennisi

Viceconti

et al. 2020

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. Here, we present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.Index Terms-Agent-Based Model, human monoclonal antibodies, In Silico Trials, SARS-CoV-2, vaccines.

show abstract

Section: B Sars-cov-2 Disease Modelmentioning

confidence: 99%

In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform

Russo

Pennisi

Viceconti

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, their maturational capacity can be affected, whereby mo-DCs may induce tolerogenic responses, regardless of the DC maturation stimulus [183][184][185]. On the other hand, it has been documented that patient-derived mo-DC functional bias is transient and tumor-dependent; in a few instances, ex vivo generated patient mo-DCs were indeed shown to recover a level of stimulatory activity that was comparable with healthy donor DCs after cancer surgery [186]. These observations suggest that the timing for apheresis could be crucial for ex vivo development of mo-DCs.…”

Section: Resultsmentioning

confidence: 99%

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

et al. 2020

View full text Add to dashboard Cite

The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.

show abstract

“…Dendritic cells (DC) are considered the most efficient antigen presenting cells and are able to regulate adaptive immunity by inducing naïve T cell activation and effector differentiation [57]. P2Y 12 receptor is expressed in murine DCs and its activation enhances specific T cell activation by increasing antigen endocytosis [19].…”

Section: Role Of Non-platelet P2y 12 Receptorsmentioning

confidence: 99%

P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation

Gaussem

Bachelot‐Loza

Nesseler

et al. 2020

IJMS

View full text Add to dashboard Cite

The P2Y12 receptor is a key player in platelet activation and a major target for antithrombotic drugs. The beneficial effects of P2Y12 receptor antagonists might, however, not be restricted to the primary and secondary prevention of arterial thrombosis. Indeed, it has been established that platelet activation also has an essential role in inflammation. Additionally, nonplatelet P2Y12 receptors present in immune cells and vascular smooth muscle cells might be effective players in the inflammatory response. This review will investigate the biological and clinical impact of P2Y12 receptor inhibition beyond its platelet-driven antithrombotic effects, focusing on its anti-inflammatory role. We will discuss the potential molecular and cellular mechanisms of P2Y12-mediated inflammation, including cytokine release, platelet–leukocyte interactions and neutrophil extracellular trap formation. Then we will summarize the current evidence on the beneficial effects of P2Y12 antagonists during various clinical inflammatory diseases, especially during sepsis, acute lung injury, asthma, atherosclerosis, and cancer.

show abstract

Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

Cited by 319 publications

References 280 publications

In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform

In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation

Contact Info

Product

Resources

About